• Publications
  • Influence
Intestinal Inhibition of the Na+/H+ Exchanger 3 Prevents Cardiorenal Damage in Rats and Inhibits Na+ Uptake in Humans
TLDR
An inhibitor of intestinal NHE3 reduces absorption of dietary sodium in rats and humans and prevents salt-induced cardiorenal injury in nephrectomized rats and suggests that therapeutic alteration of sodium transport in the gastrointestinal tract instead of the kidney could lead to improved sodium management in renal disease.
Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
TLDR
It is indicated that tenapanor is an effective inhibitor of dietary phosphorus absorption and a new approach to phosphate management in renal disease and associated mineral disorders is suggested.
The prognostic value of the EEG in asphyxiated newborns
TLDR
The study clearly demonstrates a strong correlation between the early neonatal EEG and outcome, even regarding the prediction of minor sequelae (r = 0.79, p< 0.0001), and shows the early Neonatal EEG is more accurate in predicting the ultimate clinical outcome than the Sarnat scoring.
Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice
TLDR
It is demonstrated that RDX8940, a potent, selective, minimally systemic oral TGR5 agonist, improves liver steatosis and insulin sensitivity in a mouse model of NAFLD and does not inhibit gallbladder emptying in mice, indicating that RDx8940 may have therapeutic potential in patients withNAFLD/NASH.
Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers
TLDR
Tenapanor was well tolerated and resulted in reduced intestinal sodium absorption and softer stool consistency versus placebo, and potential use of tenapanor in patients who could benefit from modification of gastrointestinal sodium balance is supported.
Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).
TLDR
A series of gut-restricted TGR5 agonists that elicit a potent response in mice, with minimal gallbladder-related effects are described, a compound with minimal systemic availability that may have therapeutic value to patients with type 2 diabetes mellitus, nonalcoholic steatohepatitis, or inflammatory bowel disease.
Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice
TLDR
The pharmacodynamic effects of RDX7675 in mice reduced intestinal potassium absorption and had a greater potassium-binding capacity than patiromer or SPS in mice, which support the potential of the calcium-based resins for the treatment of patients with hyperkalemia.
An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675
TLDR
Repeated oral dosing with RDX7675 over 4 days reduced potassium absorption in healthy volunteers; the results support QD dosing of RDX197675 in future clinical studies.
...
1
2
...